Zinc status in cystic fibrosis patients; a systematic review and meta-analysis.
| Autor: | Malekahmadi M; Imam Khomaini hospital complex, Tehran University of Medical Sciences, Tehran, Iran., Soltani S; Yazd Cardiovascular Research Center, Non-communicable Diseases Research Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran., Pahlavani N; Social Determinants of Health Research Center, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.; Health Sciences Research Center, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran., Sharifi Zahabi E; School of nutrition sciences and food technology, Kermanshah University of Medical Sciences, Kermanshah, Iran., Kazemizadeh H; Advanced Thoracic Research Center, Tehran University of Medical Sciences, Tehran, Iran., Hadavi S; Treatment Department of Tehran University of Medical Sciences, Tehran, Iran., Farsani GM; Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.; Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Heliyon [Heliyon] 2024 Jun 28; Vol. 10 (13), pp. e33686. Date of Electronic Publication: 2024 Jun 28 (Print Publication: 2024). |
| DOI: | 10.1016/j.heliyon.2024.e33686 |
| Abstrakt: | Background: Cystic fibrosis (CF) is an autosomal recessive hereditary disease causes concentration of secretions and this affects the lungs and digestive system. These patients are exposed to zinc (zn) deficiency. In this review, we decided to investigate the status of zn in CF patients compared to control group. Also, the clinical trials that have so far performed zinc supplementation in these patients are examined. Method: ISI Web of Science, Scopus, PubMed/Medline, and Cochrane database were searched, up to December 2023, for studies that reported the association between zn levels of CF patients compared to a healthy control group. A random-effect model was used to compute the pooled weighted mean difference (WMD) with 95 % confidence intervals (CI). Subgroup analysis was done for region, sample and method of measurement, zinc supplementation and age. Result: Overall, meta-analysis of 9 studies (n = 383 participants) revealed that the zn levels were significantly lower in children and adolescents with CF compared with healthy subjects (WMD = -11.97 μg/dL, 95 % CI: -22.57 to -1.37; I 2 = 92.83 %). Meta-analysis of 8 studies (n = 320 participants) revealed that the serum and plasma level of zn was significantly lower in CF patients compared with healthy subjects (WMD = -14.31 μg/dL, 95 % CI: -25.09 to -3.53; I 2 = 88.14 %, P-heterogeneity <0.001) While the zn level in saliva and sputum was significantly higher in CF patients. Conclusion: CF patients have decreased zn levels in circulatory reservoirs. zn may effective for the diminish the respiratory and gastrointestinal symptoms in CF patients, further well-designed clinical trial studies is required to prove these effects. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2024 The Authors. Published by Elsevier Ltd.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|